ZARBO, Ignazio Roberto
 Distribuzione geografica
Continente #
NA - Nord America 737
EU - Europa 388
AS - Asia 250
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 3
OC - Oceania 2
Totale 1.385
Nazione #
US - Stati Uniti d'America 734
CN - Cina 153
UA - Ucraina 125
DE - Germania 91
SG - Singapore 81
IT - Italia 71
SE - Svezia 38
CZ - Repubblica Ceca 20
FI - Finlandia 17
FR - Francia 13
GB - Regno Unito 6
KR - Corea 4
CA - Canada 3
EU - Europa 3
IN - India 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BE - Belgio 2
BR - Brasile 2
AT - Austria 1
CL - Cile 1
EE - Estonia 1
ES - Italia 1
HK - Hong Kong 1
ID - Indonesia 1
IR - Iran 1
JP - Giappone 1
ME - Montenegro 1
PH - Filippine 1
PL - Polonia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 1.385
Città #
Chandler 201
Jacksonville 78
Singapore 63
Princeton 58
Munich 43
Nanjing 28
Dearborn 25
Ashburn 22
Ann Arbor 20
Sassari 20
Wilmington 20
Beijing 18
Brno 17
Nanchang 15
New York 13
Boardman 11
Hebei 10
Mountain View 10
Santa Clara 10
Shanghai 10
Cagliari 8
Changsha 8
Jiaxing 8
Shenyang 8
Washington 7
Norwalk 5
Dallas 4
Jinan 4
Milan 4
San Francisco 4
Seoul 4
Taizhou 4
Tianjin 4
Frankfurt am Main 3
Helsinki 3
Olomouc 3
Paris 3
San Mateo 3
Vélizy 3
Brussels 2
Florence 2
Kunming 2
Los Angeles 2
Monmouth Junction 2
Ningbo 2
Romola 2
Seattle 2
Shenzhen 2
Wuxi 2
Andover 1
Augusta 1
Bologna 1
Buffalo 1
Canberra 1
Central 1
Cerreto Guidi 1
Clearwater 1
Dalian 1
Edinburgh 1
Fort Worth 1
Foshan 1
Grafing 1
Guangzhou 1
Hangzhou 1
Hanover 1
Lappeenranta 1
London 1
Los Lunas 1
Markham 1
Mumbai 1
North Vancouver 1
Nuoro 1
Perugia 1
Podgorica 1
Qingdao 1
Quanzhou 1
Redwood City 1
Reston 1
San Juan 1
Selargius 1
Surabaya 1
Sydney 1
São Paulo 1
Taichung 1
Taiyuan 1
Tallinn 1
Tashkent 1
Tehran 1
Tokyo 1
Toronto 1
Trento 1
Woodbridge 1
Zhuji 1
Totale 846
Nome #
Herv-k modulates the immune response in als patients 77
A rare case of lupus-like syndrome during treatment with interferon β-1a. 60
An innovative training program based on virtual reality and treadmill: effects on gait of persons with multiple sclerosis 58
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 57
Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis 56
First evidence of the cross-training effect in multiple sclerosis 56
Inflammation, infectious triggers, and Parkinson's disease 54
Virtual reality-treadmill training to improve gait in people with multiple sclerosis 53
Personality traits predict perceived health-related quality of life in persons with multiple sclerosis 52
Proteomic analysis of CSF in multiple sclerosis patients and controls: a study in Sardinian population 51
ADEM o sclerosi Multipla: la comunicazione di una diagnosi difficile 48
The Effect of Contralateral Strength Training on Muscle Weakness in People With Multiple Sclerosis: A Proof-of-Concept Case Series. 46
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 46
Treadmill-virtual reality combined training program to improve gait in multiple sclerosis individuals 44
A six-week intensive treadmill training improves walking ability in MS patients with moderate disability 42
Intensive treadmill training improves gait in moderately impaired multiple sclerosis individuals 42
MSRV as a prognostic factor in Sardinian patients: 10-year follow-up 41
Paresi del IX e X nervi cranici da ematoma parietale post-traumatico della carotide interna in paziente con crisi convulsiva 40
Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD 40
Sclerosi combinata del midollo, neuropatia ottica e deterioramento cognitivo post-resezione intestinale. Ruolo patogenetico della carenza di oligoelementi? 37
Long-term trajectory of acquired demyelinating syndrome and multiple sclerosis in children 34
Corpus callosum volumetrics and clinical progression in early multiple sclerosis 28
Natalizumab as treatment option of refractory epilepsy in multiple sclerosis. 27
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients 27
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study 27
HERV-W/MSRV in the CSF significantly predicts the secondary progressive MS course upon 10-years follow-up 26
Antihuman Endogenous Retrovirus Immune Response and Adaptive Dysfunction in Autism 23
Influence of psychological and social factors on self perceived health-related quality of life in patients with multiple sclerosis 20
Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder 19
A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial 18
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 18
Signs and symptoms of COVID-19 in patients with multiple sclerosis 17
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination 17
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 12
On a 5-year-old girl with multiple sclerosis treated with natalizumab 12
RNA-binding proteins in autoimmunity: From genetics to molecular biology 11
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 11
Rasagiline Withdrawal Syndrome in Parkinson’s Disease 11
Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis 10
Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies 8
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 8
Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring 8
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 8
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT) 7
Tdp‐43 and herv‐k envelope‐specific immunogenic epitopes are recognized in als patients 7
Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study 6
Network analysis of gut microbial communities reveal key genera for a multiple sclerosis cohort with Mycobacterium avium subspecies paratuberculosis infection 5
Multiple Sclerosis Progression and Relapse Activity in Children 5
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study 4
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 4
Totale 1.438
Categoria #
all - tutte 9.887
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.887


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020146 0 0 0 0 21 24 45 4 24 4 23 1
2020/2021176 20 1 24 0 22 4 22 1 32 24 18 8
2021/2022156 13 0 3 1 2 2 3 23 13 27 12 57
2022/2023366 29 48 6 61 43 47 1 34 56 20 12 9
2023/2024173 16 17 8 6 36 18 1 14 0 7 15 35
2024/2025268 77 21 136 34 0 0 0 0 0 0 0 0
Totale 1.438